We are Healthy
U.S.

Ovarian Cancer Treatment Showed Long-Term Response

New follow-up data for a combination drug therapy offers insights for patients with recurrent low-grade serous ovarian cancer.

Updated on Sept. 28, 2026 in Cancer

Isometric editorial illustration showing stylized geometric cellular structures and signaling pathways in muted earth tones, representing molecular cancer research.
A new clinical trial analysis reveals that a combination therapy of avutometinib and defactinib maintained a median response of 31 months for ovarian cancer patients. AI Illustration. Upload story photo >

Live Poll

Should cancer drugs receive accelerated approval before long-term clinical trials are completed?

Results from the RAMP 201 clinical trial indicate that a combination of avutometinib and defactinib maintained a median duration of response of 31.1 months in women with recurrent low-grade serous ovarian cancer. These two-year findings provide new data for patients navigating long-term treatment options.

Why it matters

Low-grade serous ovarian cancer is often difficult to treat, making long-term data on drug efficacy essential for clinical decision-making. These results help clarify the potential durability of this combination therapy as patients and physicians consider ongoing care plans.

The RAMP 201 Phase 2 trial followed patients for a median of 24.9 months, with the combination demonstrating a median duration of response of 31.1 months. Researchers noted that 12% of patients discontinued the treatment due to adverse events during the study period.

The players

Verastem Oncology

A biopharmaceutical company focused on developing small-molecule drugs for cancer treatment.

The details

The treatment combines oral avutometinib and defactinib, which work together to target specific cellular signaling pathways involved in cancer progression. By inhibiting these pathways, the dual-drug approach aims to slow the growth of tumors in patients with recurrent low-grade serous ovarian cancer. The study highlighted that 50% of participants with KRAS-mutated cancer and 30% of those with KRAS wild-type cancer remained on this therapy for over one year.

Timeline

  1. May 8, 2025: FDA granted accelerated approval for the combination.

  2. July 11, 2025: Primary analysis of the study was published.

  3. September 28, 2026: Two-year follow-up results were announced.

  4. October 2026: Results appear in the print edition of Gynecologic Oncology.

Health Landscape

These findings provide long-term data for an oral combination therapy in a challenging cancer category. The results establish a clinical benchmark for efficacy that the RAMP 301 international Phase 3 confirmatory trial is now working to validate on a broader scale.

If you are managing a diagnosis of low-grade serous ovarian cancer, these findings are worth discussing with your oncology team to understand how long-term data may influence your care strategy. Ask your physician about the current clinical options and whether participating in a confirmatory trial is appropriate for your situation.

The takeaway

The two-year follow-up results highlight the potential for sustained responses with this combination therapy. Patients should consult their care team to review their specific genetic profile and discuss how these clinical developments apply to their personalized treatment plan.

Further reading

For more information on current treatment standards, visit the Cancer section.

Live Poll

Should cancer drugs receive accelerated approval before long-term clinical trials are completed?